LifeMD arrives at its May 6 earnings call with a distinctive setup: short interest is heavy and still growing, yet the stock has just posted its best month in recent memory — a 19% gain — leaving bears and bulls in direct collision heading into what has historically been an explosive event.
Short positioning is a primary story here. At roughly 16.5% of the free float, short interest has climbed about 8% over the past month even as the stock rallied. The week saw a brief dip on April 28 after a spike above 17% on April 21, but the trend is clearly upward over the longer arc. What makes the positioning notable is the borrow market context: availability has tightened sharply, dropping from above 80% in mid-April to just under 60% this week. That means roughly one share is available to borrow for every two already out on loan — a market that has compressed meaningfully in ten days. Cost to borrow remains modest at 0.68% annualised, up about 11% week-on-week but not yet signalling any real squeeze risk. The ORTEX short score, at 73.3, has held in a narrow range all month — elevated and consistent, not escalating. Availability is the more active variable right now. Options positioning tells a mildly cautious story as well: the put/call ratio edged up to 0.17 on April 29, modestly above its 20-day average of 0.15 but a far cry from the 52-week high of 0.84. The z-score of 1.3 suggests limited fear rather than outright hedging activity.
The Street is decisively bullish on LFMD, with all seven analysts carrying buy-equivalent ratings as of mid-April. The most notable move in the cycle was Mizuho's upgrade in mid-March — lifting its rating to Outperform from Neutral and raising its target to $8 — which followed the Q4 earnings beat. Most other active coverage firms also lifted targets into the $8–$10 range at that point. With the stock closing at $4.43, the gap between price and consensus target is wide, reflecting both the bull thesis and the market's scepticism. The PE multiple at 18.5x and EV/EBITDA at 9x have both eased over the past 30 days as the stock gave back some of its March surge, while the earnings yield factor ranks in the 96th percentile — a data point bulls will lean on. The bear case centres on competitive pressure from lower-cost GLP-1 alternatives and revenue lumpiness as the business transitions toward branded weight-loss treatments.
The earnings history is the most dramatic element of the current setup. The last reported quarter triggered a one-day gain of more than 30%, with a five-day move of over 42%. The stock has a clear pattern of large post-earnings swings in either direction. Closest peer TDOC slipped just 0.8% on the day and is flat on the week, while SDGR and GDRX are both down roughly 4% and 3% respectively on the week — suggesting the broader digital health space is under some pressure while LFMD has held up comparatively well.
The setup heading into May 6 is unusually charged: short interest near its recent highs, availability tightening, and a stock that has twice rewarded holders with 30%-plus single-day moves on the last print. Whether the GLP-1 competitive narrative has eased enough for another positive reaction, or whether the bears are right that revenue quality has deteriorated, is the question the next report will answer.
See the live data behind this article on ORTEX.
Open LFMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
